What is the 13F Pro Quality Score for MYGN?

13F Pro ranks MYRIAD GENETICS INC (MYGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MYGN's current score at https://13fpro.ai/research/MYGN (free sign-up required for the full ranking).

Which hedge funds own the most MYGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MYGN include ORBIMED ADVISORS, BlackRock,, MILLENNIUM MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MYGN as soon as new 13F filings post.

Where does 13F Pro source MYGN data?

All MYRIAD GENETICS INC fundamentals and ownership data come directly from SEC EDGAR. MYRIAD GENETICS INC files with the SEC under CIK 899923. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MYGN in?

MYRIAD GENETICS INC (MYGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MYGN research updated on 13F Pro?

MYGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MYRIAD GENETICS INC(MYGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 899923 MYGN stock profile & AI dashboard →

13F Pro Quality Score

30.2/100

Rank #2,366 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

46.1/100

Profitability

10.2/100

Balance Sheet

2.7/100

Earnings Quality

30.0/100

Free Cash Flow

26.8/100

Institutional Flow

95.7/100

Revenue Scale

45.6/100

Dilution Risk

28.1/100

MYGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MYRIAD GENETICS INC (MYGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MYGN at 30.2/100 on a 32-signal composite quality model, placing it at rank #2,366 of 2,879 stocks — the bottom half of the AI-ranked universe. MYGN scores in the top quartile across institutional flow (95.7). Areas of concern include balance sheet strength (2.7) and profitability (10.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), MYRIAD GENETICS INC reports quarterly revenue of $200.4M, net income of $-34.1M, free cash flow of $-15.7M. Top institutional holders of MYGN by reported 13-F value include ORBIMED ADVISORS, BlackRock,, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. MYGN trades on the Nasdaq exchange and files with the SEC under CIK 899923. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MYGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MYRIAD GENETICS INC directly from SEC EDGAR. MYRIAD GENETICS INC's 13F Pro composite quality score has ranged between 8 and 47 since 2021, currently 30.2 — an improving long-term trajectory across 42 quarterly and live scoring snapshots.

✦

Fun facts about MYRIAD GENETICS INC

Quirks, history, and lore behind MYGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. molecular diagnostics company · small-cap · listed on Nasdaq · headquartered in Utah.
2
The Numbers
Annual revenue in the range of $700–800 million, driven almost entirely by genetic testing services billed to insurers and patients.
3
The History
Founded in the early 1990s, it built its business around pioneering hereditary cancer risk testing at a time when sequencing a gene was still a scientific novelty.
4
The Secret
The company once held patents on the BRCA1 and BRCA2 genes — the breast-cancer risk genes — giving it a near-monopoly on testing, until the Supreme Court struck the patents down in 2013.
5
The Lore
Angelina Jolie's 2013 op-ed about her preventive double mastectomy — triggered by a BRCA test result — sent a wave of women into genetic counseling and put this company's core product on front pages worldwide.
6
The Giveaway
Its flagship test, myRisk Hereditary Cancer, and its ticker symbol that literally contains the word "MY" — this Salt Lake City genetics lab has your DNA destiny in its name.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$200.4M

Net Income

Q3 2026

$-34.1M

Free Cash Flow

Q3 2026

$-15.7M

D/E Ratio

Q3 2026

0.36

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.3% YoY

$851.1MFY 2019

FY15 $723.1MFY16 $753.8MFY17 $771.4MFY19 $851.1M

Net Income

-73.6% YoY

$4.6MFY 2019

FY15 $79.8MFY16 $117.2MFY17 $17.4MFY19 $4.6M

Operating Income

-82.7% YoY

$7.6MFY 2019

FY15 $133.6MFY16 $153.4MFY17 $44.0MFY19 $7.6M

EPS (Diluted)

-76.0% YoY

$0.06FY 2019

FY15 $1.07FY16 $1.60FY17 $0.25FY19 $0.06

Total Assets

+29.3% YoY

$1.56BFY 2019

FY15 $766.2MFY16 $880.5MFY17 $1.21BFY19 $1.56B

Total Debt

+135.6% YoY

$233.5MFY 2019

FY15 —FY16 —FY17 $99.1MFY19 $233.5M

Op. Cash Flow

-21.2% YoY

$83.7MFY 2019

FY15 —FY16 $166.3MFY17 $106.2MFY19 $83.7M

Metric	FY 2019	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Revenue	$851.1M +10.3%	$771.4M +2.3%	$753.8M +4.2%	$723.1M -7.1%	$778.2M +26.9%	$613.2M
Net Income	$4.6M -73.6%	$17.4M -85.2%	$117.2M +46.9%	$79.8M -54.7%	$176.2M +19.7%	$147.2M
Operating Income	$7.6M -82.7%	$44.0M -71.3%	$153.4M +14.8%	$133.6M -51.3%	$274.4M +20.4%	$228.0M
EPS (Diluted)	$0.06 -76.0%	$0.25 -84.4%	$1.60 +49.5%	$1.07 -52.4%	$2.25 +27.1%	$1.77
Total Assets	$1.56B +29.3%	$1.21B +37.3%	$880.5M +14.9%	$766.2M -7.0%	$823.8M +2.5%	$803.8M
Total Debt	$233.5M +135.6%	$99.1M	—	—	—	—
Operating Cash Flow	$83.7M -21.2%	$106.2M -36.1%	$166.3M	—	—	$173.9M

AI Insight: MYGN Financial Trends

Myriad Genetics shows persistent operating losses and declining equity despite stable revenue, with debt tripling to $120M by Q3 2025.

• Revenue remained relatively flat, fluctuating between $196M and $213M across eight quarters with no clear growth trajectory.

• Operating income stayed consistently negative, ranging from -$6M to -$329M, showing inability to achieve profitability.

• Total debt increased from $39M in Q2 2024 to $120M by Q1 2026, representing a three-fold increase.

• Equity declined from $740M in Q2 2024 to $337M in Q1 2026, eroding shareholder value significantly.

⚠ Operating cash flow turned negative again in Q1 2026 at -$16M after brief positive stretch in Q4 2025.

⚠ Q2 2025 showed massive $330M net loss suggesting potential one-time charges or significant write-downs requiring investigation.

AI Insight: MYGN Ratio Trends

Myriad Genetics shows persistent unprofitability with operating margin deteriorating from -2.7% in Q4 2025 to -15.3% in Q1 2026.

• Operating margin worsened from -2.7% in Q4 2025 to -15.3% in Q1 2026, reversing prior improvement.

• ROIC declined from -4.7% in Q4 2025 to -26.8% in Q1 2026, indicating deteriorating capital efficiency.

• Debt-to-equity ratio increased from 0.05 in Q2-Q3 2024 to 0.36 in Q1 2026, showing rising leverage.

⚠ Q2 2025 showed extreme operating margin of -154.5%, suggesting potential one-time charges impacting comparisons.

⚠ Company remains unprofitable across all periods with no clear path to sustained positive margins visible.

Get alerted when MYGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MYRIAD GENETICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MYGN

ORBIMED ADVISORS LLC
$122.9M125,000,000 sh
BlackRock, Inc.
$40.0M8,889,644 sh
MILLENNIUM MANAGEMENT LLC
$30.0M6,668,817 sh
GLENVIEW CAPITAL MANAGEMENT, LLC
$24.4M5,411,978 sh
D. E. Shaw & Co., Inc.
$20.2M4,499,724 sh
STATE STREET CORP
$19.9M4,424,027 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.7M3,924,525 sh
MORGAN STANLEY
$14.3M3,168,742 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$11.6M2,582,231 sh
GOLDMAN SACHS GROUP INC
$10.6M2,366,092 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$122.9M	125,000,000
BlackRock, Inc.	$40.0M	8,889,644
MILLENNIUM MANAGEMENT LLC	$30.0M	6,668,817
GLENVIEW CAPITAL MANAGEMENT, LLC	$24.4M	5,411,978
D. E. Shaw & Co., Inc.	$20.2M	4,499,724
STATE STREET CORP	$19.9M	4,424,027
VANGUARD CAPITAL MANAGEMENT LLC	$17.7M	3,924,525
MORGAN STANLEY	$14.3M	3,168,742
VANGUARD PORTFOLIO MANAGEMENT LLC	$11.6M	2,582,231
GOLDMAN SACHS GROUP INC	$10.6M	2,366,092

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MYGN on your watchlist

Track score changes the day MYRIAD GENETICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MYGN a good stock to buy?

13F Pro's AI-powered analysis of MYRIAD GENETICS INC (MYGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MYGN are available on the MYGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MYGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MYGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MYRIAD GENETICS INC's investment landscape.